{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:02:09Z","timestamp":1787742129788,"version":"build-2784847793"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bcp.2023.115872","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T06:55:34Z","timestamp":1697871334000},"page":"115872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies"],"prefix":"10.1016","volume":"218","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7256-7316","authenticated-orcid":false,"given":"Xinlei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115872_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bcp.2023.115872_b0010","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2023.115872_b0015","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acschemneuro.9b00041","article-title":"Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets","volume":"10","author":"Paz","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bcp.2023.115872_b0020","first-page":"7","article-title":"Recent advances in understanding and managing myasthenia gravis","author":"Jordan","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.bcp.2023.115872_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2023.115872_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","article-title":"Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology","volume":"146","author":"Pham","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2023.115872_b0040","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115872_b0045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","article-title":"Myasthenia gravis: new developments in research and treatment","volume":"30","author":"Evoli","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/25785826.2020.1724756","article-title":"Antigen specific B cells in myasthenia gravis patients","volume":"43","author":"Takata","year":"2020","journal-title":"Immunol Med."},{"key":"10.1016\/j.bcp.2023.115872_b0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0060","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0065","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/ijms19061677","article-title":"The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes","volume":"19","author":"Rodr\u00edguez Cruz","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0070","doi-asserted-by":"crossref","first-page":"dev199790","DOI":"10.1242\/dev.199790","article-title":"Agrin\/Lrp4 signal constrains MuSK-dependent neuromuscular synapse development in appendicular muscle","volume":"148","author":"Walker","year":"2021","journal-title":"Development"},{"key":"10.1016\/j.bcp.2023.115872_b0075","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115872_b0080","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","article-title":"Heterogeneity in myasthenia gravis: considerations for disease management","volume":"17","author":"Evoli","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cbi.2012.08.020","article-title":"Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis","volume":"203","author":"Ohno","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115872_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104962","article-title":"The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction","volume":"299","author":"Uyen Dao","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115872_b0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cbi.2016.04.019","article-title":"Roles of collagen Q in MuSK antibody-positive myasthenia gravis","volume":"259","author":"Ohno","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115872_b0105","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596621","article-title":"Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies","volume":"11","author":"Frykman","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0120","article-title":"Anti-Kv1.4 Antibody Without Myasthenia Gravis: A Rare Cause of Autoimmune Myocarditis and Myositis","volume":"9","author":"Kuyama","year":"2023","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.bcp.2023.115872_b0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2019-322640","article-title":"Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs","volume":"91","author":"Cetin","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115872_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135013","article-title":"Rapsyn as a signaling and scaffolding molecule in neuromuscular junction formation and maintenance","volume":"731","author":"Xing","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2023.115872_b0135","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1749-6632.1998.tb10972.x","article-title":"Rapsyn antibodies in myasthenia gravis","volume":"841","author":"Agius","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0150","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00415-022-11485-1","article-title":"Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis","volume":"270","author":"Kim","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0160","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1007\/s00415-020-10263-1","article-title":"New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review","volume":"268","author":"Sriwastava","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/sjmms.sjmms_118_18","article-title":"Seronegative Myasthenia Gravis in Association with Human T-Lymphotropic Virus Type 1 and Hepatitis C","volume":"7","author":"Amin","year":"2019","journal-title":"Saudi J Med Med Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","article-title":"Epithelial Toll-like receptors and their role in gut homeostasis and disease","volume":"17","author":"Burgue\u00f1o","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2023.115872_b0190","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.neurol.2013.02.005","article-title":"The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ","volume":"169","author":"Weiss","year":"2013","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.bcp.2023.115872_b0195","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaut.2017.03.007","article-title":"Central immune tolerance depends on crosstalk between the classical and alternative NF-\u03baB pathways in medullary thymic epithelial cells","volume":"81","author":"Riemann","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2023.115872_b0205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41590-018-0128-9","article-title":"Thymic tolerance as a key brake on autoimmunity","volume":"19","author":"Cheng","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/bs.ai.2014.09.003","article-title":"Positive-selection-inducing self-peptides displayed by cortical thymic epithelial cells","volume":"125","author":"Takada","year":"2015","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0215","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.it.2012.03.005","article-title":"Thymic epithelial cells: working class heroes for T cell development and repertoire selection","volume":"33","author":"Anderson","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.it.2017.07.010","article-title":"The Mechanisms of T Cell Selection in the Thymus","volume":"38","author":"Takaba","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In Vivo CD4(+) T Cell Differentiation and Function: Revisiting the Th1\/Th2 Paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0235","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.4049\/jimmunol.174.9.5324","article-title":"Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis","volume":"174","author":"Feferman","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0240","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0250","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel Treatments in Myasthenia Gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2010.02.013","article-title":"Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia","volume":"221","author":"Shiao","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2023.115872_b0260","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","article-title":"T Cells That Help B Cells in Chronically Inflamed Tissues","volume":"9","author":"Rao","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/intimm\/dxv079","article-title":"T follicular helper cells, T follicular regulatory cells and autoimmunity","volume":"28","author":"Zhu","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0275","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nm1134","article-title":"Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells","volume":"10","author":"Polo","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2023.115872_b0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages","volume":"29","author":"Nurieva","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2023.115872_b0285","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.4049\/jimmunol.172.9.5154","article-title":"Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells","volume":"172","author":"P\u00e8ne","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0290","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1590\/0004-282x-anp-2022-s105","article-title":"Myasthenia gravis in clinical practice","volume":"80","author":"Estephan","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.bcp.2023.115872_b0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of Juvenile Myasthenia Gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0305","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0315","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.bcp.2023.115872_b0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Update on the Teratogenicity of Maternal Mycophenolate Mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J Pediatr Genet."},{"key":"10.1016\/j.bcp.2023.115872_b0325","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1002\/mus.27485","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorder secondary to mycophenolate mofetil treatment in a patient with myasthenia gravis","volume":"65","author":"Zha","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0330","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current Treatment of Myasthenia Gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2023.115872_b0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0340","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108303","article-title":"The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis","volume":"182","author":"Katz","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2023.115872_b0350","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0355","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of Oral Steroid Therapy for Myasthenia Gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0360","first-page":"257","article-title":"Treatment of Ocular Myasthenia Gravis","volume":"7","author":"Cornblath","year":"2018","journal-title":"Asia Pac J Ophthalmol (phila)."},{"key":"10.1016\/j.bcp.2023.115872_b0365","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and treatment of myasthenia gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2023.115872_b0370","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0375","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12864-017-3719-1","article-title":"Transcriptome-wide N (6) -methyladenosine methylome profiling of porcine muscle and adipose tissues reveals a potential mechanism for transcriptional regulation and differential methylation pattern","volume":"18","author":"Tao","year":"2017","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2023.115872_b0380","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0385","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/oncolo\/oyad017","article-title":"Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study","volume":"28","author":"Pelcovits","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2023.115872_b0390","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jocn.2014.03.019","article-title":"Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis","volume":"21","author":"Nagappa","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.bcp.2023.115872_b0395","doi-asserted-by":"crossref","unstructured":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394.","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"10.1016\/j.bcp.2023.115872_b0400","doi-asserted-by":"crossref","unstructured":"Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87:57-64.","DOI":"10.1212\/WNL.0000000000002795"},{"key":"10.1016\/j.bcp.2023.115872_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839075","article-title":"A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis","volume":"13","author":"Di","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0410","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2023.115872_b0415","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0420","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bcp.2023.115872_b0425","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000347068","article-title":"Tacrolimus monotherapy: a promising option for ocular myasthenia gravis","volume":"69","author":"Yagi","year":"2013","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0435","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115872_b0440","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115872_b0445","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse Effects of Immunoglobulin Therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0450","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0455","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12883-020-01901-2","article-title":"Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report","volume":"20","author":"Yanagihashi","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0460","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2023.115872_b0465","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0470","first-page":"1767","article-title":"Myasthenia Gravis and Congenital Myasthenic Syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Continuum (minneap Minn)."},{"key":"10.1016\/j.bcp.2023.115872_b0475","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0480","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0485","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0490","doi-asserted-by":"crossref","first-page":"1018509","DOI":"10.3389\/fneur.2022.1018509","article-title":"Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0495","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcp.2023.115872_b0500","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115872_b0505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0510","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3389\/fneur.2020.00981","article-title":"From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0515","article-title":"Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders","volume":"12","author":"Kaegi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0520","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14195","article-title":"Myasthenia gravis and specific immunotherapy: monoclonal antibodies","volume":"1452","author":"Cai","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0525","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0530","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0535","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0540","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2023.115872_b0545","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911784","article-title":"Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study","volume":"13","author":"Jacob","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237128","article-title":"Fermented Oyster Extract Attenuated Dexamethasone-Induced Muscle Atrophy by Decreasing Oxidative Stress","volume":"26","author":"Oh","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2023.115872_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715036","article-title":"Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0560","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0565","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement Inhibition for the Treatment of Myasthenia Gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.bcp.2023.115872_b0570","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement Inhibitor Therapy for Myasthenia Gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0575","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"<p>Complement Inhibition for the Treatment of Myasthenia Gravis<\/p>","volume":"9","author":"Mantegazza","year":"2020","journal-title":"ImmunoTargets and Therapy."},{"key":"10.1016\/j.bcp.2023.115872_b0580","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0585","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0590","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0595","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2023.115872_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0605","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2021.11.020","article-title":"Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis","volume":"95","author":"Li","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.bcp.2023.115872_b0610","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/imm.13525","article-title":"Abelson tyrosine kinase controls BCR signalling and B-cell differentiation by promoting B-cell metabolism","volume":"167","author":"Luo","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2023.115872_b0615","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2023.115872_b0620","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2012.06.019","article-title":"Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells","volume":"60","author":"Cohen","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.bcp.2023.115872_b0625","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0630","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0635","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0640","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0645","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.bcp.2023.115872_b0650","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal Antibody-Based Therapies for Myasthenia Gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.bcp.2023.115872_b0655","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JND-170211","article-title":"Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia","volume":"4","author":"Russell","year":"2017","journal-title":"J Neuromuscul Dis."},{"key":"10.1016\/j.bcp.2023.115872_b0660","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0665","first-page":"423","article-title":"Ocrelizumab: its efficacy and safety in multiple sclerosis","volume":"66","author":"Juanatey","year":"2018","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0670","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0675","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40263-022-00949-7","article-title":"Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder","volume":"36","author":"Nie","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0680","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0685","first-page":"1","article-title":"CARs: a new approach for the treatment of autoimmune diseases. Sci China","author":"Sun","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0690","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0695","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cells8121527","article-title":"CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.bcp.2023.115872_b0700","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0710","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2023.115872_b0715","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","article-title":"Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)","volume":"40","author":"Baraliakos","year":"2020","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.bcp.2023.115872_b0720","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0725","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2023.115872_b0730","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.115872_b0735","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115872_b0740","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0745","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0750","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0022-1759(91)90074-P","article-title":"Flow cytometric measurement of the respiratory burst activity of phagocytes using dihydrorhodamine 123","volume":"138","author":"Rothe","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2023.115872_b0755","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115872_b0760","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000511957","article-title":"Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report","volume":"13","author":"Vu","year":"2021","journal-title":"Case Rep Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0765","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A Review in Generalized Myasthenia Gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.115872_b0770","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0775","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0780","doi-asserted-by":"crossref","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bcp.2023.115872_b0785","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115872_b0790","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0795","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.bcp.2023.115872_b0800","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2023.115872_b0805","first-page":"22","article-title":"Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis","author":"Keller","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0810","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1021\/acschembio.1c00862","article-title":"Short FcRn-Binding Peptides Enable Salvage and Transcytosis of scFv Antibody Fragments","volume":"17","author":"Kelly","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2023.115872_b0815","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0820","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0830","first-page":"815","article-title":"Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized","volume":"11","author":"Yan","year":"2022","journal-title":"Placebo-Controlled Phase II Study. Neurol Ther."},{"key":"10.1016\/j.bcp.2023.115872_b0835","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12974-016-0475-0","article-title":"Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO\/Treg and partly dependent on FasL\/Fas pathway","volume":"13","author":"Li","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2023.115872_b0840","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12974-019-1587-0","article-title":"Exosomes derived from statin-modified bone marrow dendritic cells increase thymus-derived natural regulatory T cells in experimental autoimmune myasthenia gravis","volume":"16","author":"Zhang","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2023.115872_b0845","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/bmt.2014.251","article-title":"SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking","volume":"50","author":"Alexander","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcp.2023.115872_b0850","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp-2017-316271","article-title":"Autologous haematopoietic stem cell transplantation for neurological diseases","volume":"89","author":"Burman","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115872_b0855","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mus.27772","article-title":"Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies","volume":"67","author":"Beland","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0860","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","article-title":"Further developments with antisense treatment for myasthenia gravis","volume":"1275","author":"Sussman","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115872_b0865","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S25716","article-title":"New treatments for myasthenia: a focus on antisense oligonucleotides","volume":"7","author":"Angelini","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2023.115872_b0870","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2023.115872_b0875","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/bja\/60.5.600-b","article-title":"Unconscious perception during anaesthesia\u2013comment on statistics","volume":"60","author":"Cormack","year":"1988","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bcp.2023.115872_b0880","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?","volume":"9","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.bcp.2023.115872_b0885","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thorsurg.2018.12.011","article-title":"History of Thymectomy for Myasthenia Gravis","volume":"29","author":"Cooper","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.bcp.2023.115872_b0890","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0895","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood.V96.12.3872","article-title":"Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease","volume":"96","author":"Hoffacker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2023.115872_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102895","article-title":"Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications","volume":"132","author":"Chen","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2023.115872_b0905","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(18)30467-8","article-title":"Thymectomy in myasthenia gravis: when, why, and how?","volume":"18","author":"Berrih-Aknin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0910","first-page":"328","article-title":"Thymectomy and disease duration in non-thymomatous acetylcholine receptor antibody-positive myasthenia gravis: a single-centre, cross-sectional study","volume":"94","author":"Chung","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115872_b0915","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/mus.26919","article-title":"Update on immune-mediated therapies for myasthenia gravis","volume":"62","author":"Habib","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0920","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b0925","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2023.115872_b0930","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bcp.2023.115872_b0935","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/1759-7714.13396","article-title":"Surgical effect and prognostic factors of myasthenia gravis with thymomas","volume":"11","author":"Tian","year":"2020","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.bcp.2023.115872_b0940","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezt641","article-title":"Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis","volume":"45","author":"Leuzzi","year":"2014","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.bcp.2023.115872_b0945","doi-asserted-by":"crossref","first-page":"e28530","DOI":"10.1097\/MD.0000000000028530","article-title":"Treatment of myasthenia gravis with the method of tonifying spleen and replenishing qi in traditional Chinese medicine: A protocol for systematic review and meta-analysis","volume":"101","author":"Jiang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2023.115872_b0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.imr.2021.100806","article-title":"Chinese herbal medicine for myasthenia gravis: A systematic review and meta-analysis of randomized clinical trials","volume":"11","author":"Zhu","year":"2022","journal-title":"Integr Med Res."},{"key":"10.1016\/j.bcp.2023.115872_b0955","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases","volume":"23","author":"Miyauchi","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115872_b0960","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","article-title":"Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity","volume":"11","author":"Yang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115872_b0965","doi-asserted-by":"crossref","first-page":"6660616","DOI":"10.1155\/2021\/6660616","article-title":"Qiangji Jianli Decoction Alleviates Hydrogen Peroxide-Induced Mitochondrial Dysfunction via Regulating Mitochondrial Dynamics and Biogenesis in L6 Myoblasts","volume":"2021","author":"Song","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2023.115872_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110482","article-title":"Qiangji Jianli Decoction promotes mitochondrial biogenesis in skeletal muscle of myasthenia gravis rats via AMPK\/PGC-1\u03b1 signaling pathway","volume":"129","author":"Jiao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2023.115872_b0975","first-page":"810","article-title":"Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis","volume":"42","author":"Caifeng","year":"2022","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.bcp.2023.115872_b0980","first-page":"1217","article-title":"Artemisinin ameliorates the symptoms of experimental autoimmune myasthenia gravis by regulating the balance of TH1 cells, TH17 cells and Treg cells","volume":"32","author":"Chen","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.bcp.2023.115872_b0985","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/med.21842","article-title":"The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases","volume":"41","author":"Efferth","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2023.115872_b0990","doi-asserted-by":"crossref","first-page":"e19901","DOI":"10.1097\/MD.0000000000019901","article-title":"Acupuncture for ocular myasthenia gravis: A protocol for systematic review and meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2023.115872_b0995","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ncp.10800","article-title":"High-dose vitamin C therapy for symptomatic deficiency in a patient with myasthenia gravis and Crohn's disease","volume":"37","author":"Murphree","year":"2022","journal-title":"Nutr. Clin. Pract."},{"key":"10.1016\/j.bcp.2023.115872_b1000","doi-asserted-by":"crossref","first-page":"e0269621","DOI":"10.1371\/journal.pone.0269621","article-title":"Decreased salivary alpha-amylase activity responding to citric acid stimulation in Myasthenia gravis with malnutrition","volume":"17","author":"Huang","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115872_b1005","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13760-022-01919-y","article-title":"Physical and mental fatigue in myasthenia gravis and its correlation with other symptoms","volume":"122","author":"Akkan Suzan","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.bcp.2023.115872_b1010","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2023.115872_b1015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13063-017-2433-2","article-title":"The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial","volume":"19","author":"Birnbaum","year":"2018","journal-title":"Trials"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300463X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300463X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:08:01Z","timestamp":1731028081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522300463X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":203,"alternative-id":["S000629522300463X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115872","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115872"}}